{"id":653199,"date":"2013-04-18T13:06:06","date_gmt":"2013-04-18T17:06:06","guid":{"rendered":"http:\/\/www.pehub.com\/?p=197096"},"modified":"2013-04-18T13:06:06","modified_gmt":"2013-04-18T17:06:06","slug":"epizyme-files-for-an-ipo","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/653199","title":{"rendered":"Epizyme Files for an IPO"},"content":{"rendered":"<p>Epizyme, a six-year-old, Cambridge, Mass.-based biopharmaceutical company that&#8217;s focused on researching treatments for tumors and blood cancers, has filed an <a href=\"http:\/\/www.sec.gov\/Archives\/edgar\/data\/1571498\/000119312513160271\/d501246ds1.htm#toc501246_14\">S-1<\/a> with the SEC, in an offering whose underwriters include Citigroup, Cowen and Company, Leerink Swann, JMP Securities, and Wedbush PacGrow Life Sciences.<\/p>\n<p>Epizyme has raised more than $50 million over the years, including from Bay City Capital, Amgen Ventures, Astellas Venture Management,MPM Capital, Kleiner Perkins Caufield &amp; Byers, New Enterprise Associates, and GlaxoSmithKline.<\/p>\n<p>The filing is <a href=\"http:\/\/www.sec.gov\/Archives\/edgar\/data\/1571498\/000119312513160271\/d501246ds1.htm#toc501246_14\">here<\/a>.<\/p>\n<p>The post <a href=\"http:\/\/www.pehub.com\/197096\/epizyme-files-ipo\/\">Epizyme Files for an IPO<\/a> appeared first on <a href=\"http:\/\/www.pehub.com\/\">peHUB<\/a>.<\/p>\n<div class=\"feedflare\">\n<a href=\"http:\/\/feeds.feedburner.com\/~ff\/pehub\/news\/all?a=Bd_cW1IAdwE:pwA18c45FRE:yIl2AUoC8zA\"><img decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~ff\/pehub\/news\/all?d=yIl2AUoC8zA\" border=\"0\"><\/img><\/a> <a href=\"http:\/\/feeds.feedburner.com\/~ff\/pehub\/news\/all?a=Bd_cW1IAdwE:pwA18c45FRE:dnMXMwOfBR0\"><img decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~ff\/pehub\/news\/all?d=dnMXMwOfBR0\" border=\"0\"><\/img><\/a> <a href=\"http:\/\/feeds.feedburner.com\/~ff\/pehub\/news\/all?a=Bd_cW1IAdwE:pwA18c45FRE:D7DqB2pKExk\"><img decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~ff\/pehub\/news\/all?i=Bd_cW1IAdwE:pwA18c45FRE:D7DqB2pKExk\" border=\"0\"><\/img><\/a> <a href=\"http:\/\/feeds.feedburner.com\/~ff\/pehub\/news\/all?a=Bd_cW1IAdwE:pwA18c45FRE:7Q72WNTAKBA\"><img decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~ff\/pehub\/news\/all?d=7Q72WNTAKBA\" border=\"0\"><\/img><\/a> <a href=\"http:\/\/feeds.feedburner.com\/~ff\/pehub\/news\/all?a=Bd_cW1IAdwE:pwA18c45FRE:V_sGLiPBpWU\"><img decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~ff\/pehub\/news\/all?i=Bd_cW1IAdwE:pwA18c45FRE:V_sGLiPBpWU\" border=\"0\"><\/img><\/a> <a href=\"http:\/\/feeds.feedburner.com\/~ff\/pehub\/news\/all?a=Bd_cW1IAdwE:pwA18c45FRE:qj6IDK7rITs\"><img decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~ff\/pehub\/news\/all?d=qj6IDK7rITs\" border=\"0\"><\/img><\/a> <a href=\"http:\/\/feeds.feedburner.com\/~ff\/pehub\/news\/all?a=Bd_cW1IAdwE:pwA18c45FRE:l6gmwiTKsz0\"><img decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~ff\/pehub\/news\/all?d=l6gmwiTKsz0\" border=\"0\"><\/img><\/a>\n<\/div>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~r\/pehub\/news\/all\/~4\/Bd_cW1IAdwE\" height=\"1\" width=\"1\"\/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Epizyme, a six-year-old, Cambridge, Mass.-based biopharmaceutical company that&#8217;s focused on researching treatments for tumors and blood cancers, has filed an S-1 with the SEC, in an offering whose underwriters include Citigroup, Cowen and Company, Leerink Swann, JMP Securities, and Wedbush PacGrow Life Sciences. Epizyme has raised more than $50 million over the years, including from [&hellip;]<\/p>\n","protected":false},"author":7567,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-653199","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/653199","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/7567"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=653199"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/653199\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=653199"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=653199"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=653199"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}